TAKEDA PHARMACEUTICAL COMPANY LTD. v. TEVA PHARMACEUTICALS USA, INC.

Civ. No. 07-331-SLR.

TAKEDA PHARMACEUTICAL COMPANY LTD., TAKEDA PHARMACEUTICALS NORTH AMERICA, INC., TAKEDA PHARMACEUTICALS LLC, TAKEDA PHARMACEUTICALS AMERICA, INC., and ETHYLPHARM, S.A., Plaintiffs, v. TEVA PHARMACEUTICALS USA, INC. and TEVA PHARMACEUTICAL INDUSTRIES LTD., Defendants.

United States District Court, D. Delaware.

November 9, 2009.


Attorney(s) appearing for the Case

Steven J. Balick, Esquire, John G. Day, Esquire, and Lauren E. Maguire, Esquire of Ashby & Geddes, Wilmington, Delaware. Counsel for Plaintiffs. Of Counsel for Plaintiffs Takeda Pharmaceuticals LLC and Takeda Pharmaceuticals America, Inc.: Stuart E. Pollack, Esquire of DLA Piper LLP, New York, New York. Of Counsel for Plaintiff Takeda Pharmaceutical Company, Ltd.: Arlene L. Chow, Esquire, Dillon Kim, Esquire, and Eric J. Lobenfeld, Esquire of Hogan and Hartson LLP, New York, New York; Phillippe Y. Riesen, Esquire of Hogan and Hartson LLP, Tokyo Japan. Of Counsel for Plaintiff Takeda Pharmaceuticals North America, Inc.: Chad J. Peterman, Esquire of Patterson Belknap Webb & Tyler LLP, New York, New York; Stuart E. Pollack, Esquire of DLA Piper LLP, New York, New York. Of Counsel for Plaintiff Ethypharm, S.A.: Paul A. Ragusa, Esquire, Lisa Kole, Esquire, and Sandra Lee, Esquire of Baker Botts, LLP, New York, New York; Arlene L. Chow, Esquire, Dillon Kim, Esquire, and Eric J. Lobenfeld, Esquire of Hogan and Hartson LLP, New York, New York; Phillippe Y. Riesen, Esquire of Hogan and Hartson LLP, Tokyo Japan.

Karen L. Pascale, Esquire, John W. Shaw, Esquire, and Josy W. Ingersoll, Esquire of Young, Conaway, Stargatt & Taylor LLP, Wilmington, Delaware. Counsel for Defendants and Counterclaim Plaintiffs. Of Counsel: John L. North, Esquire, Jeffrey J. Toney, Esquire, Ann G. Fort, Esquire and Laura F. Fritts, Esquire of Sutherland Asbill & Brennan LLP, Atlanta, Georgia.


OPINION

SUE L. ROBINSON, District Judge.

I. INTRODUCTION

Takeda Pharmaceutical Company, Ltd., Takeda Pharmaceuticals North America Inc., Takeda Pharmaceuticals LLC and Takeda Pharmaceuticals America, Inc. (collectively, "Takeda") are the exclusive licensees of U.S. Patent No. 5,464,632 ("the '632 patent"), which claims a rapidly disintegrating oral tablet.1 Takeda is the holder of an approved New Drug Application (...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases